Alvameline (Lu 25-109) is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It acts as a muscarinic receptor agonist, which makes it a candidate for treating conditions like Alzheimer's disease, where enhancing cholinergic activity can improve cognitive function. Additionally, its modulation of serotonin receptors suggests potential use in managing mood disorders such as depression or anxiety. Research also explores its role in addressing symptoms of schizophrenia, particularly in improving cognitive deficits and negative symptoms. Its dual action on both muscarinic and serotonin receptors positions it as a versatile compound for targeting complex brain disorders. However, further clinical studies are needed to fully establish its efficacy and safety in these applications.